Docetaxel or abiraterone, in addition to standard care, are very effective treatments for men with prostate cancer due to start long-term hormone therapy. Findings from the STAMPEDE trial and STOPCAP network meta-analysis, helping clinicians to choose between them, were published recently in Annals of Oncology. The STAMPEDE trial, directly compared men recruited to the trial between November 2011 and March 2013. Patients were randomised to receive either docetaxel plus standard hormone therapy, or abiraterone plus standard hormone therapy. This is the first direct randomised data comparing the two treatments. The STOPCAP network meta-analysis represents the most comprehensive and reliable assessment of the effects of current treatment options for men whose prostate cancer has spread, and who are starting long-term hormone therapy for the first time.  Results based on all current trial data show that abiraterone plus standard hormone therapy is most likely to be the best treatment; do ...

As the STAMPEDE trial recruits its 10,000th participant, we would like to mark this milestone and take the opportunity to thank everyone involved, particularly participants and their families, all the hundreds of hospital staff involved and the staff at the MRC CTU at UCL. It would not be possible to help improve care for men with advanced prostate cancer without the dedication and continued involvement of all of these people. Impact on treatments for patients with prostate cancer STAMPEDE is the largest ever prostate cancer treatment trial. The study has already demonstrated improved survival with the addition of either docetaxel or abiraterone to standard-of-care treatment for men starting long-term hormone therapy. The clinical results from STAMPEDE on docetaxel were published in early 2016 and have changed the treatment for men with prostate cancer worldwide. Docetaxel is now available on the NHS to men with cancer that has spread to distant parts of their body. However, it is ...


MRC Clinical Trials Unit at UCL
2nd Floor
90 High Holborn



Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy

See the latest News in STAMPEDE through the link to the right.